ArticleAdvances in radiation oncology2026
Stereotactic Body Radiation Therapy for Symptomatic Benign Spinal Tumors: A Single-Center Retrospective Experience.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Benign spinal tumors (BSTs) are relatively uncommon, though can yield significant morbidity as related to location and size. Surgical resection is the primary management modality for symptomatic lesions; however, for patients who are nonsurgical candidates or have progressed post-surgery, radiation therapy can be employed for definitive treatment. This institutional series describes the local control and toxicity outcomes of stereotactic body radiation therapy (SBRT) for BST. Methods and Materials: Patients treated with SBRT for BST at a single institution from 2010 to 2021 were retrospectively reviewed and analyzed. Patients were included if they underwent treatment with SBRT with or without prior surgical intervention. Evaluation of posttreatment toxicities, symptomatic improvement, imaging response, and local control were performed. Results: During the study period 31 patients were identified with a total of 36 BST. The distribution of the tumors included 16 in the cervical spine (44%), 13 thoracic (n = 36%), and 7 lumbosacral (n = 20%). Histologies included 14 schwannoma (39%), 12 meningioma (33%), and 8 hemangioma (22%), 1 melanocytic tumor (3%), and 1 neurofibroma (3%). Median radiation prescription dose was 25 Gy (range, 18-40 Gy) in 5 fractions (range, 3-5 fractions). Of the treated lesions, 17 (47%) had prior surgical management and 19 (53%) were treated upfront with SBRT. With median imaging follow-up was 49 months (range, 2-171) and the median clinical follow-up was 83 months (range, 10-171) with 86% of assessable patients having stable to improved symptoms in the treated lesion at 12 months. Two patients demonstrated progressive disease on imaging. There were no incidences of National Cancer Institute Common Terminology Criteria for Adverse Events version 4 grade 3 or greater observed toxicities and the most common toxicities were fatigue 6 (17%), and pain flare 5 (14%), both transient. There was no association between treatment course (prior surgery versus definitive radiation) and symptomatic stability or improvement, imaging response, or toxicity. Conclusions: SBRT is well tolerated for treatment of symptomatic BST with high rates of symptomatic stability or improvement. This series demonstrated acceptable local control and no high-grade toxicities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.